DNLI Insider Trading Activity and SEC Form 4 Filings
DNLI insider trading summary
Over the past 12 months, insiders at Denali Therapeutics Inc. (DNLI) reported 6 sales worth $1.3M by 3 insiders and no open-market purchases on SEC Form 4. Net insider selling was $1.3M.
Latest DNLI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Nancy Thornberry | Director | Sell | $247K (10,824 @ $22.85) |
| Sep 2, 2026 | Nancy Thornberry | Director | Sell | $15K (615 @ $23.74) |
| Sep 1, 2026 | Alexander O. Schuth | COFO and Secretary | Sell | $65K (2,768 @ $23.44) |
| Aug 11, 2026 | Alexander O. Schuth | COFO and Secretary | Sell | $72K (2,857 @ $25.07) |
| Jan 6, 2026 | Ryan J. Watts | President and CEO | Sell | $581K (35,198 @ $16.50) |
| Jan 6, 2026 | Alexander O. Schuth | COFO and Secretary | Sell | $284K (17,218 @ $16.50) |
| Aug 13, 2025 | Carole Ho | Chief Medical Officer | Sell | $12K (806 @ $14.64) |
| Aug 12, 2025 | Alexander O. Schuth | COFO and Secretary | Sell | $40K (2,937 @ $13.58) |
| Aug 12, 2025 | Carole Ho | Chief Medical Officer | Sell | $40K (2,937 @ $13.58) |
| Jul 9, 2025 | Ryan J. Watts | President and CEO | Sell | $7.4M (495,282 @ $15.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.